key: cord-0755446-wlid5bn9
authors: Abdo Cuza, Anselmo A; Ávila, Jonathan Pi; Martínez, Rafael Machado; González, José Jordán; Aspuro, Guillermo Pérez; Gutiérrez Martínez, Juan A; Suzarte, Mayra Ramos; Hernández, Danay Saavedra; Añé-Kouri, Ana L; Ramos, Tania Crombet
title: Nimotuzumab for COVID-19: case series
date: 2021-11-22
journal: Immunotherapy
DOI: 10.2217/imt-2021-0269
sha: 0c46661696b6d0c3db693df09415f976d53a58a7
doc_id: 755446
cord_uid: wlid5bn9

Background: In COVID-19, EGFR production is upregulated in the alveolar epithelial cells. EGFR overexpression further activates STAT-3 and increases lung pathology. The EGFR pathway is also one of the major nodes in pulmonary fibrosis. Methods: Nimotuzumab, a humanized anti-EGFR antibody, was used to treat three patients with severe or moderate COVID-19. The antibody was administered in combination with other drugs included in the national COVID-19 protocol. Results: Nimotuzumab was well tolerated. IL-6 decreased from the first antibody infusion. Clinical symptoms significantly improved after nimotuzumab administration, and the CT scans at discharge showed major resolution of the lung lesions and no signs of fibrosis. Conclusion: Safe anti-EGFR antibodies like nimotuzumab may modulate COVID-19-associated hyperinflammation and prevent fibrosis. Clinical Trial Registration: RPCEC00000369 (RPCEC rpcec.sld.cu).

antibody, in combination with radiation and chemotherapy, significantly increases the survival and objective response rate of patients with advanced epithelial tumors [29] [30] [31] [32] [33] [34] [35] .

Nimotuzumab has previously been shown by immunohistochemistry to decrease IL-6 in mice xenografted with pancreatic cell lines overexpressing EGFR. This result was confirmed by western blot and real-time PCR [36] .

In view of the well-proven role of EGFR in inflammation [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] and fibrosis [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , an expanded access protocol for RPCEC00000369 was launched in patients with severe and moderate COVID-19. The study is ongoing and here we describe the outcomes in three patients receiving the antibody at the Center for Medical and Surgical Research.

A noncontrolled, multicenter clinical trial was carried out to evaluate the preliminary safety and effect of nimotuzumab in patients with confirmed SARS-CoV-2 infection by real-time PCR (RT-PCR). The clinical trial included patients with severe or moderate illness. Severe patients were individuals with an oxygen saturation (SpO 2 ) <94 % on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen <300 mm Hg, a respiratory rate of 30 breaths/min or lung infiltrates >50%. Moderate patients were those subjects who showed evidence of lower respiratory disease during clinical assessment or imaging and who had SpO 2 ≥94% on room air at sea level. The main efficacy variables were: rate of patients recovered 14 days after the first infusion, rate of patients requiring mechanical ventilation after nimotuzumab, and length of stay in the hospital. Inflammatory parameters like CRP, ferritin, LDH and IL-6 were measured over time. Patients were able to receive other treatments included in the national protocol for the management of COVID-19, including steroids, anticoagulants and antibiotics.

Here we report the results in three patients with confirmed SARS-CoV-2 infection classified as severely (patients 1 and 2) or moderately ill (patient 3) who were included in the referred trial. The study was approved by an ethical review board and by the National Regulatory Agency. All patients provided informed consent for the investigational treatment.

Nimotuzumab was administered by the intravenous route at a loading dose of 200 mg diluted in 250 ml of sodium chloride (0.9%). Patients could receive a second or third dose of the monoclonal antibody (100 mg) if they still had laboratory or radiological signs of inflammation. The infusion duration was 2 h. Laboratory exams included routine bloods, leukocyte subsets and the following biochemical parameters: LDH, ferritin, CRP, D-dimer, aspartate aminotransferase, bilirubin, creatinine and procalcitonin. IL-6 levels were measured using a commercially available kit from R&D Systems (MN, USA), the human IL-6 Quantikine ELISA Kit (Cat no. S6050).

A 54-year-old female patient with a personal history of Type 2 diabetes mellitus, hypertension and obesity presented at the emergency room with shortness of breath, cough with whitish expectoration and nasal secretion. She had had symptoms for the previous 3 days and had worsening dyspnea. At physical examination, the patient had mild edema in the lower limbs, reduced thoracic expandability, decreased vesicular murmur and a respiratory rate of 27 breaths per minute. Her room-air SpO 2 was 72% and she was admitted to the intensive care unit. She had fever of 38 • C and her general performance status was markedly deteriorated. Her condition was classified as severe.

Upon her admission, SARS-CoV-2 infection was confirmed by RT-PCR. At hospital entry, the patient required supplemental oxygen and started treatment with remdesivir (loading dose of 200 mg, then 100 mg for 5 days), dexamethasone (8 mg orally), meropenem (1 g intravenously every 8 h) and low-molecular-weight heparin.

After deterioration of the clinical and inflammatory markers in the first 24 h, the medical team decided to start nimotuzumab administration at a loading dose of 200 mg by the intravenous route. At that moment, the oxygenation index (SpO 2 /FiO 2 ) was 228; then two additional infusions of nimotuzumab at a dose of 100 mg every 3 days were administered. No adverse events were detected after any of the infusions. Overall, the patient had a stable respiratory evolution, requiring supplemental oxygen for 8 days but not mechanical ventilation. Remarkably, after the first nimotuzumab infusion, her IL-6 concentration dropped from 112 pg/ml to levels below 1.5 pg/ml and did not increase after this initial reduction (Table 1) . Ferritin and CRP levels significantly decreased after two antibody doses. Table 1 shows the evolution of laboratory markers from baseline to hospital discharge at day 12. Figure 2 displays comparative images of the axial CT scans performed at admission and every 6 days, showing improvement of the bilateral inflammatory lesions.

A 62-year-old female patient with a personal history of hypertension and overweight was admitted at the hospital after 14 days of marked asthenia and nausea. SARS-CoV-2 positivity was confirmed by RT-PCR. At physical examination, she had crackles in the right lung base and sporadic cough. The room-air SpO 2 was 88%, which rose to 95% with supplemental oxygen at 2 l/min. On the first day of admission, treatment began with oral dexamethasone 6 mg/day, remdesivir (loading dose of 200 mg, then 100 mg/day up to five doses), aspirin, lowmolecular-weight heparin and nimotuzumab (200 mg loading dose followed by two 100 mg doses on days 4 and 7). No adverse events occurred after any of the antibody infusions. The evolution of the patient was satisfactory. Within 24 h of the first antibody administration, IL-6 decreased from 120 to 3.97 pg/ml and then to 1.5 pg/ml (Table 1) . Ferritin and CRP decreased after the second nimotuzumab dose. Aspartate aminotransferase was elevated at baseline and started to decrease after the initial therapy. Table 1 shows the results of the laboratory markers, while Figure 2 displays the imaging evolution by CT scan. The patient was discharged on day 7 after a marked clinical, laboratory and radiological improvement.

A 55-year-old, overweight male patient presented at the emergency room because he was a contact of a positive SARS-CoV-2 case. He was asymptomatic but the RT-PCR result was positive. The patient was admitted at the hospital and started therapy with favipiravir and azithromycin; 2 days later, he complained of nasal secretion and asthenia. On day 3 of admission, dexamethasone (8 mg/day) was added after the detection of peripheral inflammatory lesions at the CT scan together with IL-6 increase (from 1.5 to 10 pg/ml). On day 4, he complained of headache and fever of 38 • C. After 2 days of treatment with dexamethasone, his clinical symptoms continued to worsen and the fever, headache and marked general discomfort persisted. The IL-6 level increased to 25.2 pg/ml and ferritin from 689 to 919 ng/ml, while the CT scan showed worsening of the inflammatory lesions. Considering the deteriorations in clinical symptoms and radiological and inflammatory markers, nimotuzumab was prescribed (200 mg loading dose, followed by 100 mg 72 h later). The antibody was well tolerated. After nimotuzumab, the clinical symptoms improved, IL-6 decreased to 1.5 pg/ml and there was a significant recovery of the radiological lesions. The patient was discharged on day 9 of hospital admission. Figure 2 & Table 1 show the evolution of imaging and laboratory markers, respectively. 

To date, there is no specific treatment for SARS-CoV-2 infection. In general, therapeutic alternatives for patients include the combination of antiviral, anticoagulant and anti-inflammatory drugs [51, 52] . Among the latter, in addition to steroids, some immunomodulatory drugs such as tocilizumab, baricitinib and itolizumab, commonly used to treat autoimmune disorders, have been employed in COVID-19 patients [53] [54] [55] [56] . These anti-inflammatory drugs are prescribed in combination with steroids to reduce the so-called cytokine release syndrome or cytokine storm that characterize the hyperinflammatory stage of COVID-19 [57] . In a large randomized trial (RECOVERY), 4116 patients were enrolled to receive an anti-IL-6 receptor inhibitor or usual care. Most of the patients also received concomitant steroid therapy. Globally, tocilizumab improved survival of the hospitalized COVID-19 patients with hypoxia and systemic inflammation. There were three serious adverse reactions [54] . Likewise, baricitinib (a small inhibitor of JAK) plus standard of care, including systemic corticosteroids and antivirals, significantly decreased mortality compared with placebo [58] .

Here we report the use of a humanized anti-EGFR antibody to treat three patients with severe or moderate COVID-19. The use of an anti-EGFR antibody theoretically offers, in the same drug, the modulation of hyperinflammation [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] and the prevention of fibrosis [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] .

Nimotuzumab was administered in combination with remdesivir or favipiravir, dexamethasone, low-molecularweight heparin and antibiotics. At hospital admission, all three patients had a poor prognosis in view of their comorbidities. Two patients were severely ill, considering their hypoxemic acute respiratory failure and oxygen requirements. The antibody did not cause any adverse events. In general, nimotuzumab is a very safe drug because it has an intermediate affinity against EGFR which facilitates preferential uptake by tissues with high EGFR expression [27] . Most frequent nimotuzumab-related events in cancer comprise mild or moderate anorexia, chills, headache, fatigue and fever; nimotuzumab does not induce skin rash or hypomagnesemia like other EGFR-targeting drugs [29] .

After adding nimotuzumab to the standard of care, IL-6 concentrations decreased to almost undetectable levels in all three subjects. Remarkably, IL-6 was very high (>110 pg/ml) in the two patients with severe disease. Moreover, in patients 1 and 3, the IL-6 concentration was rising despite therapy including steroids, aspirin and anticoagulants. Lactate dehydrogenase also decreased from the first nimotuzumab dose, while ferritin and CRP declined after two antibody infusions. The three patients had a rapid and significant clinical improvement. The CT scans at discharge showed a major resolution of the lung lesions and no signs of fibrosis. Pulmonary function tests, together with lung ultrasound echocardiography and new CT scans, will be done as part of the patients' follow-up.

We hypothesize that safe EGFR antagonists, like nimotuzumab, might reduce the morbidity and mortality associated with SARS-CoV-2 infection. More than 1000 severely or moderately ill patients have already been treated with the antibody in combination with other drugs included in the national protocol for COVID-19. The analysis of the complete series is ongoing.

Safe EGFR-targeting drugs might also be used to treat acute respiratory distress syndrome, associated with acute hypoxemia, pulmonary damage and fibrosis.

• In COVID-19, EGFR is upregulated in the type II alveolar epithelial cells after the STAT-1 reduction and the acute lung damage. • EGFR overexpression further activates STAT-3 and increases lung pathology.

• The EGFR pathway is also one the major nodes in pulmonary fibrosis.

• Nimotuzumab is a humanized antibody that recognizes EGFR.

• Three severe or moderate COVID-19 patients with multifocal interstitial pneumonia were treated with nimotuzumab in combination with antiviral, anticoagulant and steroid therapy. • Treatment was safe and no adverse events were detected.

• Nimotuzumab, combined with the standard of care, reduced circulating IL-6 concentrations in the 3 COVID- 19 patients. • Other inflammatory markers (ferritin, LDH, CRP and neutrophil-lymphocyte ratio) also declined after antibody therapy. • The three patients showed rapid clinical and radiological improvement.

• Safe anti-EGFR antibodies like nimotuzumab may modulate COVID-19 associated hyperinflammation and prevent of fibrosis.

Evolution patterns of SARS-CoV-2: snapshot on its genome variants

An aberrant STAT pathway is central to COVID-19

Discloses the expression of EGFR after reduction of STAT-1 and lung damage

EGFR: an essential receptor tyrosine kinase-regulator of cancer stem cells

• Explains the role of EGFR in the regulation of cancer stem cells

Epidermal growth factor receptor targeting in cancer

Acute lung injury: a clinical and molecular review

Human epidermal growth factor receptor signaling in acute lung injury

Pathogenesis of acute respiratory distress syndrome

Molecular and clinical features of EGFR-TKI-associated lung injury

ADAM17/EGFR-dependent ERK activation mediates thrombin-induced CTGF expression in human lung fibroblasts

EGF and PDGF receptor tyrosine kinases as therapeutic targets for chronic lung diseases

Gefitinib prevents bleomycin-induced lung fibrosis in mice

Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis

Secreted phospholipase A2-IIA modulates transdifferentiation of cardiac fibroblast through EGFR transactivation: an inflammation-fibrosis link

Lung cancer and interstitial lung disease: a literature review

The EGFR-ADAM17 axis in chronic obstructive pulmonary disease and cystic fibrosis lung pathology

Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities

Overactive epidermal growth factor receptor signaling leads to increased fibrosis after severe acute respiratory syndrome coronavirus infection

The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis

Explains the role of the EGFR pathway in pulmonary fibrosis, mucus secretion, inflammatory response and tissue repair

Viral fibrotic scoring and drug screen based on MAPK activity uncovers EGFR as a key regulator of COVID-19 fibrosis

Mass spectrometry-based proteomic platforms for better understanding of SARS-CoV-2 induced pathogenesis and potential diagnostic approaches

COVID-19 candidate genes and pathways potentially share the association with lung cancer

The main receptors involved with COVID-19: a systematic review and meta-analysis

Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs

Connecting the Dots: Interplay of Pathogenic Mechanisms between COVID-19 Disease and Mucormycosis

Computational analysis of microRNA-mediated interactions in SARS-CoV-2 infection

Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity

Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients

antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody

Nimotuzumab for patients with inoperable cancer of the head and neck

A randomised Phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial

Efficacy and safety of concurrent chemoradiotherapy with or without nimotuzumab in unresectable locally advanced squamous cell carcinoma of head and neck: prospective comparative study -ESCORT-N study

Correction to: results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood

EGFR-targeting as a biological therapy: understanding nimotuzumab's clinical effects

Use of nimotuzumab combined with cisplatin in treatment of nasopharyngeal carcinoma and its effect on expressions of VEGF and MMP-2

Phase 2 study of nimotuzumab in combination with concurrent chemoradiotherapy in patients with locally advanced non-small-cell lung cancer

EGFR high expression, but not KRAS status, predicts sensitivity of pancreatic cancer cells to nimotuzumab treatment in vivo

Cytokine response is determined by duration of receptor and signal transducers and activators of transcription 3 (STAT3) activation

EGFR inhibitors from cancer to inflammation: discovery of 4-fluoro-N-(4-(3-(trifluoromethyl)phenoxy)pyrimidin-5-yl)benzamide as a novel anti-inflammatory EGFR inhibitor

Cellular senescence or EGFR signaling induces Interleukin 6 (IL-6) receptor expression controlled by mammalian target of rapamycin (mTOR)

IL-6 in inflammation, autoimmunity and cancer

The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment

Regulation of epidermal growth factor receptor expression and morphology of lung epithelial cells by interleukin-1β

Gramine attenuates EGFR-mediated inflammation and cell proliferation in oral carcinogenesis via regulation of NF-kappaB and STAT3 signaling

Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer

Role of epidermal growth factor receptor (EGFR) and its ligands in kidney inflammation and damage

Inhibition of epidermal growth factor receptor attenuates LPS-induced inflammation and acute lung injury in rats

Lung cancer models reveal severe acute respiratory syndrome coronavirus 2-induced epithelial-to-mesenchymal transition contributes to coronavirus disease 2019 pathophysiology

Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing inflammation and oxidative stress

STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor

Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment

COVID-19: current understanding of its pathophysiology, clinical presentation and treatment

• Overview of the COVID-19 pathophysiology

Treatment for COVID-19: an overview

Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dexamethasone in hospitalized patients with COVID-19

Baricitinib plus remdesivir for hospitalized adults with covid-19

Cytokine storm and mucus hypersecretion in COVID-19: review of mechanisms

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled Phase 3 trial

T Crombet, M Ramos Suzarte, D Saavedra Hernández and AL Añé-Kouri designed the clinical trial, informed consent and CRFs of the expanded access trial; AA Abdo, J PiÁvila, R Machado, J Jordán, G Pérez and JA Gutiérrez administered the experimental drug plus SOC and followed the COVID-19 patients at the hospital intensive care unit; AA Abdo and T Crombet drafted the manuscript.All authors reviewed and approved the final manuscript

The authors are very grateful to all physicians, nurses and general staff working with hospitalized COVID-19 patients.

This study was funded by the Cuban Ministry of Health and the Center of Molecular Immunology. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.

The authors state that they have followed the principles outlined in the Declaration of Helsinki for human experimental investigations. The study was approved by an ethical review board and by the National Regulatory Agency. All patients provided informed consent for the investigational treatment and for publication.

The authors certify that this manuscript reports original clinical trial data on three patients (RPCEC00000369). Individual participant data that underlies the results reported in the article, after de-identification are available along with the study protocol. The data will be available 9 months after article publication and will end 36 months following article publication. The information will be shared with investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose and for individual participant data meta-analysis. Proposals may be submitted up to 36 months following article publication. After this date the data will be available in our data warehouse but without investigator support other than deposited metadata. Information regarding submitting proposal and accessing data may be found at https://rpcec.sld.cu/ensayos/RPCEC00 000369-Sp. or https://rpcec.sld.cu/en/trials/RPCEC00000369-En.

This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/